Unresectable Hepatocellular Carcinoma Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Unresectable Hepatocellular Carcinoma market is segmented by Treatment (Chemotherapy, Molecularly Targeted Therapy, Immunotherapy, Others), by End-User (Hospital Pharmacies, Drug Stores, Online Pharmacies), and Geography

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.4 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Unresectable Hepatocellular Carcinoma market studied is anticipated to grow with a CAGR of nearly 5.4%, during the forecast period.

  • Certain factors that are driving the market growth include high incidence rate of liver carcinoma and advancement in new treatment options.
  • The change in the current lifestyle has led to the exposure of a large amount of population to certain risk factors that contribute to liver cancer. The risk factors include hepatitis (caused by either the hepatitis B or hepatitis C virus), type 2 diabetes, metabolic disorders and excess body weight, alcohol consumption, and tobacco smoking. Liver cancer risk increases substantially with the increase in one’s body mass index (BMI). More than half of the adult population in the United States falls under the category referred to as overweight.
  • According to American Cancer Society estimates, there would be around 42,810 new liver cancer cases in the United States in 2020. Moreover, the high demand for therapeutic drugs for hepatocellular carcinoma will create wide opportunities for the manufacturers to produce more drugs and thereby, the market is expected to witness a high CAGR over the forecast period.

Scope of the Report

Unresectable HCC is defined as a type of liver tumor not eligible for resection therapy given the extent of disease, including patients that were not suitable for surgery for location of tumor(s) in the liver, or patients who were older than 75 years, or those who refused surgical therapies.

By Treatment
Molecularly Targeted Therapy
By End-user
Cancer Centers
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Chemotherapy Holds Significant Share in the Global Unresectable Hepatocellular Carcinoma Market

Chemotherapy is one of the most important treatment modalities for advanced hepatocellular carcinoma (HCC). On the basis of the results of two pivotal Phase III placebo-controlled studies, sorafenib is currently acknowledged worldwide as the standard therapeutic agent for advanced HCC. Following the introduction of sorafenib for the treatment of HCC, Phase III trials of numerous other agents as first-line or second-line chemotherapy have been conducted to determine if any of these agents might offer superior survival benefit to sorafenib. In 2016, a clear survival benefit of regorafenib over placebo was demonstrated in HCC patients showing disease progression after sorafenib treatment. A year later, in 2017, lenvatinib has been shown to be non-inferior to sorafenib, in terms of the overall survival, in chemo-naïve patients with advanced HCC. More recently, promising outcomes have also been reported with new agents, such as nivolumab and cabozantinib. At present, various novel combination regimens including these agents are currently under development.

seg uhc.PNG

North America Dominates the Global Unresectable Hepatocellular Carcinoma Market

Hepatocellular carcinoma is one of the major causes leading to cancer-related deaths worldwide. It is observed that the Asian and African countries have higher incidence rates of hepatocellular carcinoma than the developed world, due to the disparity in the major risk factors causing hepatocellular carcinoma, such as hepatitis C virus (HCV) and hepatitis B virus (HBV) infection in those regions.

As per the data published by the National Organization for Rare Diseases (NORD), there are approximately six new cases of HCC per every 100,000 people in the general population of the United States. With the increase in the incidence of hepatocellular carcinoma, there is expected to be a huge demand for the therapeutics. Hence, the rising incidence of cancer and high unmet medical needs are the major factors that drive the market across the region in the forecast period.

final geo uhc.png

Competitive Landscape

The global Unresectable Hepatocellular Carcinoma market is moderately competitive and consists of a few major players. Companies like Astrazeneca Plc, Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Pfizer Inc, among others, hold the substantial market share in the market.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 High incidence rate of liver carcinoma

      2. 4.2.2 Advancement in new treatment options

    3. 4.3 Market Restraints

      1. 4.3.1 Less diagnosis and poor efficacy of current therapeutic agents

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Treatment

      1. 5.1.1 Chemotherapy

      2. 5.1.2 Molecularly Targeted Therapy

      3. 5.1.3 Immunotherapy

      4. 5.1.4 Others

    2. 5.2 By End-user

      1. 5.2.1 Hospitals

      2. 5.2.2 Cancer Centers

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Astrazeneca Plc

      2. 6.1.2 Bayer AG

      3. 6.1.3 Bristol-Myers-Squibb Company

      4. 6.1.4 Celgene Corporation

      5. 6.1.5 Eisai Co., Ltd.

      6. 6.1.6 F. Hoffmann-La Roche Ltd

      7. 6.1.7 Merck & Co., Inc.

      8. 6.1.8 Pfizer Inc

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Unresectable Hepatocellular Carcinoma Market market is studied from 2018 - 2026.

The Unresectable Hepatocellular Carcinoma Market is growing at a CAGR of 5.4% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Bristol-Myers Squibb Company , F. Hoffmann-La Roche Ltd , Eisai Co., Ltd., Bayer AG, Merck & Co., Inc. are the major companies operating in Unresectable Hepatocellular Carcinoma Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!